AHA ACLS vs CardioGenetics

The AHA ACLS app is the American Heart Association's (AHA) officially endorsed digital health solution to assist clinicians in running codes and delivering bedside ACLS care with actual patients. The app was developed by Harvard-trained physicians, in collaboration with the AHA, to help fellow physicians, nurses, physician assistants, nurse practitioners, and EMTs deliver the highest level of advanced cardiac life support (ACLS) at the point-of-care. It began as a project to assist clinicians within Massachusetts General Hospital (MGH), a Harvard Medical School teaching hospital—and then expanded to have a global scope after significant positive impact was demonstrated. Importantly, real-time feedback from our clinician users continuously drives improvements in app design, features, and function so that you will have the best experience providing life-saving care at the bedside. The AHA ACLS app is the only one to have all content vetted by both the AHA science team and practicing Harvard-affiliated physicians. It also features the latest 2025 release of AHA recommendations for ACLS. We owe it to our patients to use the best digital health tools to give them the highest chance of surviving acute life-threatening cardiac illnesses. To this end, we have developed a low cost, intuitive, and rigorously vetted mobile app to assist clinicians— including in all stages of training—and enhance ACLS care at the bedside. Features: - Intuitive design to rapidly access 4 ACLS algorithms (i.e. cardiac arrest, tachycardia with pulse, bradycardia with pulse, and post cardiac arrest care) - Includes all recently released 2025 ACLS content including drug therapy and dosing, reversible causes, etc. - Easy-to-read timers and ability to log rounds of CPR, epinephrine, and defibrillations - Button within cardiac arrest algorithm that allows for rapid transition to post cardiac arrest care pathway once patient achieves ROSC - All content rigorously vetted by AHA science team and practicing Harvard-affiliated physicians We continue to iterate based on real-time clinician feedback, so that you will have the best experience providing life-saving care at the bedside. AHA ACLS offers an auto-renewing annual subscription at $3.99/year with a 3-day free trial. You will have unlimited access to all content while you maintain an active subscription. Payment will be charged to the credit card connected to your Apple ID Account when you confirm the initial subscription purchase. Subscriptions automatically renew unless auto-renew is turned off at least 24-hours before the end of the current subscription period. Your account will be charged for renewal within 24-hours prior to the end of the current period. You may manage your subscription and auto-renewal may be turned off by going to your Account Settings after the purchase. Any unused portion of the free trial period, if offered, will be forfeited when you purchase a subscription. You can read more about our terms and conditions in the app.

Every inherited cardiomyopathy evaluation warrants meticulous, accurate, and evidence-based risk stratification. CardioGenetics compiles validated calculators, diagnostic frameworks, and a live clinical trial finder in your pocket. USED AT THE BEDSIDE Whether you are presenting at a multidisciplinary cardiomyopathy board, interpreting a new pathogenic variant, or seeing your first LMNA patient, CardioGenetics gives the same tools with the evidence and models behind every number. ASCVD RISK ALIGNED WITH THE 2026 GUIDELINES Calculate 10-year risk with AHA PREVENT (ages 30–79), compare against the legacy Pooled Cohort Equations, integrate coronary artery calcium via the MESA score, and interpret Lipoprotein(a) with a built-in risk multiplier. Every result maps directly to the 2026 ACC/AHA dyslipidemia guideline statin thresholds, risk-enhancing factors, and CAC decision pathways. GENE-SPECIFIC SUDDEN CARDIAC DEATH RISK Not all cardiomyopathies carry the same arrhythmic risk. CardioGenetics includes dedicated calculators for HCM (ESC 2014 Risk-SCD), ARVC (Cadrin-Tourigny), LMNA (Wahbi, ESC 2023-adapted), PLN p.Arg14del (Verstraelen), DSP (ERADOS, Eur Heart J 2024), FLNC (Gigli, JAMA Cardiol 2025), and PKP2-specific guidance. Each cross-referenced to the latest ESC 2023 and AHA/ACC 2024 guidelines. DIAGNOSTIC FRAMEWORKS AT YOUR FINGERTIPS Confirm diagnoses before you risk-stratify. Built-in criteria include the 2020 Padua Criteria for arrhythmogenic cardiomyopathy, AHA/ACC 2024 and ESC 2023 HCM diagnostic standards, LVNC scoring (Jenni, Petersen, Stöllberger), and DCM phenotyping. FIND THE RIGHT CLINICAL TRIAL Browse actively enrolling studies for Lp(a), HCM, ACM/ARVC, DSP, LMNA, and PLN with interactive U.S. state and European enrollment maps. Every trial includes its NCT identifier and a direct link to ClinicalTrials.gov. DESIGNED FOR WHAT WE ACTUALLY DO IN CLINIC • Search any calculator, diagnosis, or trial from a single search bar • Tap a risk score and see the full mathematical model, original citation, and DOI • View sensitivity analyses and interactive risk curves • Share lay-language summaries during patient-facing discussions • Cross-navigate between diagnostic confirmation and risk stratification in one tap TRUST BUT VERIFY: Every calculator reproduces its published equation with full variable definitions and baseline coefficients. There are no "black boxes" here, no proprietary modifications. Tap any citation to access the original published manuscript. INTENDED USERS: Cardiologists · Electrophysiologists · Genetic Counselors · Cardiology Fellows and Residents · Medical Students · Advanced Practice Providers · Inherited Cardiovascular Disease Teams Developed by Mark E. Pepin, MD, PhD, FESC. All risk models are derived from peer-reviewed literature and their original sources. This app is a clinical decision-support aid for healthcare professionals and does not replace clinical judgment, institutional protocols, or shared decision-making. Not FDA-cleared or CE-marked.